

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO. | FILING DA | ATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. | |
|-----------------------|-----------------|-----------|-------------------------|---------------------|------------------|--|
| 10/511,796 | 10/19/20 | 004 | Koji Sode | TOYA126.002APC | 1880 | |
| 20995 | 7590 08/02/2005 | | | EXAM | EXAMINER | |
| KNOBBE 1 2040 MAIN | MARTENS OL | МЕАН, МОН | MEAH, MOHAMMAD Y | | | |
| FOURTEENTH FLOOR | | | | ART UNIT | PAPER NUMBER | |
| IRVINE, CA 92614 | | | 1652 | | | |
| | | | DATE MAILED: 08/02/2005 | | | |

Please find below and/or attached an Office communication concerning this application or proceeding.

| | | Application No. | Applicant(s) | | | |
|---|---|-----------------------|-----------------------------|--|--|--|
| | | 10/511,796 | SODE, KOJI | | | |
| | Office Action Summary | Examiner | Art Unit | | | |
| | | Mohammad Meah | 1652 | | | |
| | The MAILING DATE of this communication app | | | | | |
| Period fo | · • | | | | | |
| A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). | | | | | | |
| Status | | | | | | |
| 1)🖂 | Responsive to communication(s) filed on 10/19 | <u>)/2004</u> . | | | | |
| 2a) <u></u> □ | This action is FINAL . 2b)⊠ This action is non-final. | | | | | |
| 3)□ | Since this application is in condition for allowance except for formal matters, prosecution as to the merits is | | | | | |
| | closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. | | | | | |
| Dispositi | on of Claims | | | | | |
| 4)⊠ | 4)⊠ Claim(s) <u>1-31</u> is/are pending in the application. | | | | | |
| - | 4a) Of the above claim(s) is/are withdrawn from consideration. | | | | | |
| 5) | 5) Claim(s) is/are allowed. | | | | | |
| • | Claim(s) is/are rejected. | | | | | |
| · | Claim(s) is/are objected to. | | | | | |
| 8)⊠ | Claim(s) <u>1-31</u> are subject to restriction and/or e | election requirement. | | | | |
| Applicati | on Papers | | • | | | |
| 9) | The specification is objected to by the Examine | г. | | | | |
| 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. | | | | | | |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). | | | | | | |
| Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). | | | | | | |
| 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. | | | | | | |
| Priority u | ınder 35 U.S.C. § 119 | | | | | |
| 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: | | | | | | |
| , | 1. Certified copies of the priority documents have been received. | | | | | |
| | 2. Certified copies of the priority documents have been received in Application No | | | | | |
| 3. Copies of the certified copies of the priority documents have been received in this National Stage | | | | | | |
| application from the International Bureau (PCT Rule 17.2(a)). | | | | | | |
| * See the attached detailed Office action for a list of the certified copies not received. | | | | | | |
| | | | | | | |
| Attach | *(e) | | | | | |
| Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) | | | | | | |
| 2) Notic | 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date | | | | | |
| | mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) or No(s)/Mail Date | 6) Other: | atent Application (PTO-152) | | | |
| S. Patent and Trademark Office | | | | | | |

Application/Control Number: 10/511,796

Art Unit: 1652

DETAILED ACTION

The claims 1-31 are pending in the instant office action.

Restriction

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I claim 1, drawn to glucose dehydrogenase β -subunit.

Group II claim(s) 2-7 and 12- 23 drawn to DNA encoding protein of group I, vector, transformant and methods of production of protein of group I.

Group III claims 8-11 and 24-31, drawn to DNA, vector, transformant and methods of production of glucose dehydrogenase complex.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The proteins of Group I, nucleotides, vector and host cell of group II-III are each unrelated and chemically distinct entities.

Furthermore; the technical feature linking group I- III appears to be that they all relate to

Art Unit: 1652

glucose dehydrogenase β -subunit. The protein, glucose dehydrogenase β -subunit, of group I do not constitute a "special technical feature" as defined by PCT Rule 13.2, because it does not claim a feature, which defines a contribution over the prior art as protein within group I is taught by Nagakawa et al.(US PUB US2004/0245121 A1 page 2-3, paragraph 26-27).

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mohammad Meah whose telephone number is 571-272-1261. The examiner can normally be reached on 8:30-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax

Art Unit: 1652

phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Mohammad Younus Meah, PhD

Examiner, Art Unit 1652

Recombinant Enzymes, 3C31 Remsen Bld 400 Dulany Street, Alexandria, VA 22314

Telephone: 517-272-1261